CRISPR Therapeutics AG (CRSP) Shares Outstanding (Weighted Average) (2015 - 2026)

CRISPR Therapeutics AG has disclosed Shares Outstanding (Weighted Average) across 12 years of filings, most recently posting $96.1 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $96.1 million, up 11.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $96.1 million (up 11.77% YoY), and the FY2025 annual result was $89.9 million, up 6.6% from the prior year.
• Shares Outstanding (Weighted Average) came in at $96.1 million for Q1 2026 at CRISPR Therapeutics AG, up from $89.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $96.1 million in Q1 2026 to a low of $77.1 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $81.8 million (2024), against an average of $82.9 million.
• Across the five-year window, Shares Outstanding (Weighted Average) gained 1.9% in 2023 and rose 11.77% in 2026, its largest moves.
• CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) stood at $77.7 million in 2022, then climbed by 1.9% to $79.2 million in 2023, then increased by 6.49% to $84.4 million in 2024, then increased by 6.6% to $89.9 million in 2025, then gained by 6.81% to $96.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $96.1 million (Q1 2026), $89.9 million (Q4 2025), and $91.3 million (Q3 2025), per Business Quant data.